Abbott Park, Illinois Wednesday, November 20, 2024, 13:00 Hrs [IST] ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...

The "Surgical Microscopes - Market Insights, Competitive Landscape, Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.The surgical microscopes market was valued at USD 1.02 ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

MedAware, an AI platform improving patient safety, demonstrates the shift from rule-based systems to data-driven, ...